cyclin δ-3 Inhibitors

Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Cyclin δ-3 is known to form complexes with CDKs, and the inhibition of CDK4/6 by Palbociclib could prevent Cyclin δ-3 from exerting its role in cell cycle progression, thereby inhibiting its function.

Ribociclib functions similarly to Palbociclib as it selectively inhibits CDK4 and CDK6. Its inhibition of these kinases would prevent the Cyclin δ-3 from associating with CDKs and participating in cell cycle regulation, leading to functional inhibition of Cyclin δ-3.

Abemaciclib is another selective CDK4 and CDK6 inhibitor. By binding to these kinases, Abemaciclib would impair the formation of Cyclin δ-3-CDK complexes that are essential for cell cycle progression, thus inhibiting Cyclin δ-3's function.

Dinaciclib is a potent CDK inhibitor with activity against CDK1, CDK2, CDK5, and CDK9. While not as selective for CDK4/6, its broad inhibition of CDKs could disrupt Cyclin δ-3's activity in the cell cycle by preventing its interaction with various CDK partners.

Flavopiridol strongly inhibits several CDKs, including CDK1, CDK2, CDK4, and CDK6. This broad-spectrum inhibition could lead to a decrease in Cyclin δ-3 activity by blocking its ability to associate with its CDK partners and participate in the cell cycle.

Roscovitine is a CDK inhibitor with selectivity towards CDK2, CDK7, and CDK9, and to a lesser extent CDK1 and CDK5. Inhibition of these kinases could indirectly inhibit Cyclin δ-3 by disrupting its regulatory interactions involved in the cell cycle.

SNS-032 is a potent inhibitor of CDK2, CDK7, and CDK9. By inhibiting these kinases, SNS-032 may indirectly inhibit Cyclin δ-3 function by preventing its association with these kinases, thus impairing its role in the cell cycle and transcription regulation.